To improve long-term persistence and reduce the risk of immune rejection, researchers are exploring ways to diminish the ...

Aucatzyl is the first CAR-T cell therapy approved by the FDA with no requirement for a risk evaluation mitigation strategy ...

Glioblastoma is the most common kind of malignant brain tumor in adults. So far, no treatment has been able to make this ...

These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target ...

2seventy Bio focuses on pioneering cell and gene therapies. Its lead product, Abecma, is a chimeric antigen receptor (CAR) ...

A recent meta-analysis investigating cardiovascular complications in adults undergoing chimeric antigen receptor (CAR) T-cell ...

WA Cancer Fellowships support research and training for medical practitionersFunds awarded for two projects to improve care for people with ...

Data presented as part of a poster at the SITC 2024 Conference SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- ...

The FDA has approved obecabtagene autoleucel (Aucatzyl) to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Obe-cel was designed to increase T-cell persistence and reduce T-cell exhaustion and was shown to improve response rates and survival, particularly in patients with low leukemia burden.

About Hemogenyx Pharmaceuticals plc Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and ...

1 Obe-cel is a chimeric antigen receptor (CAR) T-cell therapy that is the first approved by the FDA without a requirement for ...